Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Novellus Systems, Inc. (“Novellus” or the “Company”) (NASDAQ: NVLS) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Lam Research Corporation (“Lam”) (NASDAQ: LRCX) in an all-stock deal valued at about $3.3 billion. Under the terms of the proposed transaction, Novellus stockholders will receive 1.125 shares of Lam for each share of Novellus common stock they own. Based on the closing price of Lam’s stock on December 16, 2011, the deal values Novellus at $40.41 per share, while according to Yahoo! Finance, at least one financial analyst has set a price target of $51.75 for Novellus.

Request more information now by clicking here: www.faruqilaw.com/NVLS

Whether Novellus’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether the proposed transaction undervalues Novellus’s shares and by how much this proposed transaction undervalues the Company to the detriment of Novellus’s shareholders are the key focus of this investigation.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in Novellus and wish to obtain additional information, please visit us at www.faruqilaw.com/NVLS or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2011 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

If you liked this article you might like

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger

These 5 Stocks Under $10 Could Make You a Lot of Money

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

5 Stocks Under $10 Set to Soar